Review
doi: 10.14694/EDBK_157801.
Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer
Affiliations
- PMID: 27249733
- DOI: 10.14694/EDBK_157801
Item in Clipboard
Review
Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer
Am Soc Clin Oncol Educ Book.
2016.
Free article
Abstract
Immune surveillance is well recognized as an important mechanism to prevent development or progression of head and neck cancers. Head and neck cancer cells can escape the immune system through multiple mechanisms including development of tolerance in T cells and inhibition of T-cell-related pathways, generally referred to as checkpoint inhibitors. This article highlights advances in immuno-oncology treatment approaches in recurrent and metastatic head and neck squamous cell carcinoma. Clinical trials are discussed in detail, with an emphasis on response dynamics, oncologic efficacy, safety, and tolerability of checkpoint inhibitors. In addition, developing concepts and ongoing studies in this setting are also reviewed.
Similar articles
-
Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.Eur J Cancer. 2017 May;76:152-166. doi: 10.1016/j.ejca.2016.12.035. Epub 2017 Mar 18. Eur J Cancer. 2017. PMID: 28324750 Free PMC article. Review.
-
Manipulating the Immune System With Checkpoint Inhibitors for Patients With Metastatic Sarcoma.Am Soc Clin Oncol Educ Book. 2016;35:e558-64. doi: 10.1200/EDBK_161901. Am Soc Clin Oncol Educ Book. 2016. PMID: 27249767 Review.
-
L’immunothérapie dans les cancers ORL.Bull Cancer. 2018 Dec;105 Suppl 1:S35-S42. doi: 10.1016/S0007-4551(18)30388-6. Bull Cancer. 2018. PMID: 30595197 Review. French.
-
Nivolumab in recurrent/metastatic head and neck cancers.Future Oncol. 2018 Mar;14(7):603-609. doi: 10.2217/fon-2017-0440. Epub 2017 Nov 13. Future Oncol. 2018. PMID: 29130342
-
Recent advances in the clinical development of immune checkpoint blockade therapy.Cell Oncol (Dordr). 2019 Oct;42(5):609-626. doi: 10.1007/s13402-019-00456-w. Epub 2019 Jun 14. Cell Oncol (Dordr). 2019. PMID: 31201647 Review.
Cited by
-
Genomics and advances towards precision medicine for head and neck squamous cell carcinoma.Laryngoscope Investig Otolaryngol. 2017 Aug 22;2(5):310-319. doi: 10.1002/lio2.86. eCollection 2017 Oct. Laryngoscope Investig Otolaryngol. 2017. PMID: 29094075 Free PMC article. Review.
-
Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.Drug Des Devel Ther. 2017 Aug 31;11:2537-2549. doi: 10.2147/DDDT.S119537. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28919706 Free PMC article. Review.
-
Coexistence of sarcoidosis and metastatic lesions: A diagnostic and therapeutic dilemma.Oncol Lett. 2017 Dec;14(6):7643-7652. doi: 10.3892/ol.2017.7247. Epub 2017 Oct 20. Oncol Lett. 2017. PMID: 29344212 Free PMC article.
-
The Association Between Lung Cancer and Sarcoidosis: A Literature Review.Cureus. 2023 Sep 18;15(9):e45508. doi: 10.7759/cureus.45508. eCollection 2023 Sep. Cureus. 2023. PMID: 37868478 Free PMC article. Review.
-
LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma.Oncoimmunology. 2016 Oct 7;5(11):e1239005. doi: 10.1080/2162402X.2016.1239005. eCollection 2016. Oncoimmunology. 2016. PMID: 27999760 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
